Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
RBGPF
62.0100
The Fort Worth Press - Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
USD
-
AFN 72.408785
ALL 87.540161
AMD 389.683553
ANG 1.790158
AOA 918.000367
ARS 1074.091897
AUD 1.590331
AWG 1.8
AZN 1.70397
BAM 1.721579
BBD 2.014876
BDT 121.253466
BGN 1.726423
BHD 0.376568
BIF 2966.682804
BMD 1
BND 1.317724
BOB 6.895823
BRL 5.862604
BSD 0.997931
BTN 85.914352
BWP 13.918401
BYN 3.265789
BYR 19600
BZD 2.004489
CAD 1.38695
CDF 2874.50392
CHF 0.815472
CLF 0.025326
CLP 985.229523
CNY 7.292104
CNH 7.28581
COP 4322.521016
CRC 512.037322
CUC 1
CUP 26.5
CVE 97.059989
CZK 22.117504
DJF 177.527398
DKK 6.575604
DOP 61.634611
DZD 131.64604
EGP 51.286475
ERN 15
ETB 129.670789
EUR 0.880304
FJD 2.279504
FKP 0.766325
GBP 0.764409
GEL 2.760391
GGP 0.766325
GHS 15.492642
GIP 0.766325
GMD 72.131977
GNF 8659.875159
GTQ 7.708747
GYD 209.125212
HKD 7.75354
HNL 25.821965
HRK 6.632504
HTG 131.474117
HUF 361.252155
IDR 16818.004844
ILS 3.69874
IMP 0.766325
INR 86.15626
IQD 1307.324982
IRR 42181.274409
ISK 128.31846
JEP 0.766325
JMD 158.002657
JOD 0.70904
JPY 143.489504
KES 129.638578
KGS 87.08707
KHR 4000.331785
KMF 434.308983
KPW 899.930375
KRW 1419.607148
KWD 0.30654
KYD 0.828261
KZT 518.289865
LAK 21659.284537
LBP 89831.715941
LKR 298.487762
LRD 199.874406
LSL 19.176166
LTL 2.95274
LVL 0.60489
LYD 5.559528
MAD 9.324358
MDL 17.731979
MGA 4531.390872
MKD 54.16639
MMK 2099.592364
MNT 3516.423721
MOP 7.99031
MRU 39.496907
MUR 44.132172
MVR 15.44397
MWK 1730.812727
MXN 20.317404
MYR 4.422532
MZN 63.81496
NAD 19.176166
NGN 1598.648403
NIO 36.765831
NOK 10.660965
NPR 137.914633
NZD 1.716989
OMR 0.384969
PAB 1
PEN 3.729351
PGK 4.123919
PHP 56.951925
PKR 280.467475
PLN 3.788327
PYG 8011.695905
QAR 3.640374
RON 4.394877
RSD 103.45387
RUB 83.597266
RWF 1414.76649
SAR 3.750373
SBD 8.455386
SCR 14.532428
SDG 600.117533
SEK 9.76727
SGD 1.319745
SHP 0.785843
SLE 22.780371
SLL 20969.501083
SOS 567.679756
SRD 36.676906
STD 20697.981008
SVC 8.75037
SYP 13001.705362
SZL 19.176166
THB 33.471772
TJS 10.867955
TMT 3.498021
TND 3.00272
TOP 2.405774
TRY 38.072865
TTD 6.79013
TWD 32.285265
TZS 2677.148909
UAH 41.363502
UGX 3674.610345
UYU 42.95221
UZS 12958.255622
VES 77.113493
VND 25729.101097
VUV 123.792316
WST 2.82166
XAF 579.078644
XAG 0.030971
XAU 0.000309
XCD 2.705466
XDR 0.744469
XOF 579.078644
XPF 105.346026
YER 245.371627
ZAR 19.114504
ZMK 9001.203587
ZMW 28.22628
ZWL 321.999592
- Markram, Pooran lead Lucknow to IPL win over Gujarat
- First US-Iran nuclear talks in years take place in Oman
- Boulard double takes Women's Six Nations contenders France past Wales
- Piastri leads McLaren 1-2 in Bahrain final practice
- Alcaraz beats Davidovich Fokina to reach first Monte Carlo final
- De Bruyne inspires Man City revival to crush Palace
- Israel seizes key Gaza corridor, to expand offensive
- UK lawmakers hold emergency debate to save British Steel
- Warnings issued, flights cancelled as strong winds whip north China
- End of the line for Hong Kong's Democratic Party
- Markram, Pooran lead Lucknow to IPL win over Gujarat
- First US-Iran nuclear talks in years take place in Oman
- Boulard double takes Women's Six Nations contenders France past Wales
- Piastri leads McLaren 1-2 in Bahrain final practice
- Alcaraz beats Davidovich Fokina to reach first Monte Carlo final
- De Bruyne inspires Man City revival to crush Palace
- Israel seizes key Gaza corridor, to expand offensive
- UK lawmakers hold emergency debate to save British Steel
- Warnings issued, flights cancelled as strong winds whip north China
- End of the line for Hong Kong's Democratic Party
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19.
"We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna. "This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians vulnerable to RSV in the future."
RSV is a highly contagious respiratory virus that causes a substantial burden of disease, particularly in older adults. In the 2024 Australian winter period, RSV laboratory-notified cases in adults aged 65 and older were nearly two-thirds the number of influenza cases in the same age group.2 90% of RSV-related deaths reported nationally occurred in those aged 60 years and older, underscoring its potential for severe impact on older Australians.2
The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.
About mRESVIA (Respiratory Syncytial Virus Vaccine)
mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes.
To date, Moderna has received marketing authorizations for its RSV vaccine in the United States, the European Union, Canada, Qatar, the United Arab Emirates, Taiwan, and the United Kingdom and has submitted regulatory applications in other markets worldwide.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Australian Therapeutic Goods Administration (TGA) granting approval for mRESVIA® (mRNA-1345); the potential for mRESVIA to reduce disease burden from RSV; and Moderna's pending marketing authorization applications for mRNA-1345. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
International Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.Mirceawillats@modernatx.com
Australia Media:
Jemimah Brennan
Director, Communications & Corporate Affairs, Australia
jemimah.brennan@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
References
Australian Register of Therapeutic Goods (ARTG) Information - https://www.tga.gov.au/resources/artg/411450
Australian Respiratory Surveillance Report 11 - 29 July to 11 August 2024, https://www.health.gov.au/resources/publications/australian-respiratory-surveillance-report-11-12-august-to-25-august-2024 accessed 7 March 2025.
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
N.Patterson--TFWP
